Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-3.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$27.42M+13.3%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$44.87M+22.5%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s free cash flow?
IDEAYA Biosciences, Inc. (IDYA) reported free cash flow of -$76.14M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s free cash flow changed year-over-year?
IDEAYA Biosciences, Inc.'s free cash flow decreased by 23.5% year-over-year, from -$61.67M to -$76.14M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s free cash flow?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s free cash flow has grown at a 5.9% compound annual growth rate (CAGR), from -$58.42M to -$73.47M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.